

RESEARCH

Open Access



Identification of biomarkers, immune infiltration landscape, and treatment targets of ischemia–reperfusion acute kidney injury at an early stage by bioinformatics methods

Ruilian You¹, Zhige Heyang², Yixin Ma¹, Peng Xia¹, Hua Zheng¹, Jianfeng Lin¹, Peili Ji¹ and Limeng Chen^{1*}

Abstract

Background: Mechanisms underlying ischemia/reperfusion injury-acute kidney injury (IRI-AKI) are not fully elucidated. We conducted an integrative analysis of IRI-AKI by bioinformatics methods.

Methods: We screened gene expression profiles of the IRI-AKI at early phase from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified and enrichment pathways were conducted based on gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) database, and Gene set enrichment analysis (GSEA). Immune cell infiltration analysis was performed to reveal the change of the microenvironment cell types. We constructed protein–protein interaction (PPI), and Cytoscape with plug-ins to find hub genes and modules. We performed robust rank aggregation (RRA) to combine DEGs and analyzed the target genes for miRNA/transcription factor (TF) and drug-gene interaction networks.

Results: A total of 239 and 384 DEGs were identified in GSE87024 and GSE34351 separately, with the 73 common DEGs. Enrichment analysis revealed that the significant pathways involve mitogen-activated protein kinase (MAPK) signaling, interleukin-17, and tumor necrosis factor (TNF) signaling pathway, etc. RRA analysis detected a total of 27 common DEGs. Immune cell infiltration analysis showed the plasma cells reduced and T cells increased in IRI-AKI. We identified JUN, ATF3, FOS, EGR1, HMOX1, DDIT3, JUNB, NFKBIZ, PPP1R15A, CXCL1, ATF4, and HSPA1B as hub genes. The target genes interacted with 23 miRNAs and 116 drugs or molecular compounds such as curcumin, staurosporine, and deferoxamine.

Conclusion: Our study first focused on the early IRI-AKI adopting RRA analysis to combine DEGs in different datasets. We identified significant biomarkers and crucial pathways involved in IRI-AKI and first construct the immune landscape and detected the potential therapeutic targets of the IRI-AKI by drug-gene network.

Keywords: Ischemia/reperfusion injury, Acute kidney injury, Robust rank aggregation, Immune infiltration, Drug-gene interaction network

Background

Acute kidney injury (AKI), characterized by a rapid decrease in glomerular filtration rate, is a universal disease in hospital with high morbidity and mortality. It is reported that the incidence of AKI is 10–15% of all hospitalizations [1] and approximately 50% in the intensive

*Correspondence: chenlimeng@pumch.cn

¹ Department of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China
Full list of author information is available at the end of the article



care unit [2]. The ischemia–reperfusion injury (IRI) is the most common cause of AKI [3], which often occurs after surgery and contributes to adverse outcomes in kidney transplantation. The mismatch between supply and demand of oxygen is the central pathophysiology of the IRI/AKI leading to oxidative metabolism reduction and further injury of tubular epithelial cells [4]. Though several biomarkers, such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and interleukin-18 (IL-18), have been studied for a long time, no one can substitute the creatinine in the clinical setting since low specificity to predict and diagnose AKI. Scientists haven't found pharmacological therapy to prevent or reverse the damage once kidney injury is established. Renal replacement therapy is the only alternative treatment available for severe AKI patients currently [5]. An in-depth understanding of the molecular and cellular pathophysiological mechanisms underlying IRI-AKI will contribute to exploring a more precision approach to detect and treat kidney injury.

Microarray, a high-throughput tool for powerfully performing global gene expression profiles. At present, many studies have applied microarray to explore potential biomarkers and pathways in disease development [6, 7], which provides instructions for further experiments. Since seldom IRI-AKI patients receive kidney biopsy, human kidney specimen is hard-acquired in genome-wide transcriptional analysis. We investigated the transcriptional pathogenesis and progressions of IRI-AKI based on the data from experimental animal models which were widely used in this field.

With the development of bioinformatics, several methods have been applied to screen the key biomarkers and pathways involved in the IRI-AKI. However, limited sample sizes of individual studies and the use of different technological platforms lead to substantial inter-study variability. The robust rank aggregation (RRA) is an effective method to integrate differentially expressed genes (DEGs) lists of different platforms, which is both computationally efficient and statistically stable. This method has been used in many disorders, such as gastric cancer [8], papillary thyroid carcinoma [9], and diabetic nephropathy [10], but hasn't been applied in IRI-AKI thus far. Here, we extracted the samples with the same tissue type and similar genetic background IRI-AKI mice from GSE87024 and GSE34351 datasets in GEO database. We adopted the RRA method to find common DEGs and gene pathways. Further protein–protein interaction (PPI), gene–miRNA/transcription factor (TF) network, and drug–gene interaction network were performed to improve the in-depth understanding of the IRI-AKI (Fig. 1).

Materials and methods

Microarray data and normalization

We searched the "acute kidney injury [MeSH Terms] OR acute kidney failure [All fields] OR "renal ischemia–reperfusion injury" OR "ischemic AKI" AND "Expression profiling by array"[Filter]" in the Gene Expression Omnibus (GEO) (<http://www.ncbi.nlm.nih.gov/geo>). The inclusion is: (1) The study focused on the ischemia–reperfusion injury. (2) The sample tissue is the kidney. (3) The organism is wild-type mice. (4) The IRI-AKI time is early within 24 h. Besides, considering detecting the biomarkers of AKI as early as possible and reducing the heterogeneity of different datasets, we chose the two datasets (GSE87024 and GSE34351) published in high-level journals without being analyzed well before (Table 1). For GSE87024, we extracted the IRI-6 h (GSM2319037, GSM2319038, GSM2319039) and sham group (GSM2319034, GSM2319035, GSM2319036) and for GSE34351, we chose the IRI-4 h ($n=3$, GSM847661, GSM847662, GSM847663) and control group of wild-type mice ($n=3$, GSM847664, GSM847665, GSM847666). The method of performing the IRI-AKI model in the dataset GSE34351 was clipping the left renal for either 16 min or 23 min after right nephrectomy, which was like the dataset GSE87024 making the left renal occluded for 17.5 min.

The platform for GSE87024 is GPL6887, Illumina MouseWG-6 v2.0 expression beadchip, while GSE34351 is GPL1261 [Mouse430_2], Affymetrix Mouse Genome 430 2.0 Array. Normalization of these data was carried out with the "limma" R package.

Identification of differentially expressed genes

We applied the linear model and empirical Bayes model analysis by the "limma" R package to find the DEGs and calculate the differential expression. The $|\log_2\text{fold change (FC)}| > 1.5$ and $p\text{-value} < 0.05$ were used as the significant criteria. Heatmaps and volcano plots of DEGs were conducted using the "Pheatmap" and "ggplot2" packages in R. 4.0.0. An unsupervised principal component analysis (PCA) method was performed to extract two features from each group. The overlapping DEGs were further visualized by the "VennDiagram" R package.

Functional and pathway enrichment analysis

We conducted the Gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DEGs in different datasets. GO analysis can find the biological characteristics in the biological process (BP) of the genes. KEGG analysis offers a comprehensive knowledge of bio-interpretation of cellular processes and identifies shared pathways of co-expressed genes. We completed and visualized the




Table 1 Characteristics of the individual studies

GEO ID	Platform	Published Time	Organism	Strain	Tissue Type	IRI time	Sample size	Citation (PMID)	Citation (Journal)
GSE87024	GPL6887	2016	Mus musculus	C57BL/6	IRI vs Sham kidney	6 h	3 vs 3	26,823,548	JASN
GSE34351	GPL1261	2012	Mus musculus	C57BL/10	IRI vs Sham kidney	4 h	3 vs 3	22,895,517	KI

GEO Gene Expression Omnibus, IRI Ischemic renal injury

JASN Journal of American Society of Nephrology, KI Kidney International

analysis by the "ClusterProiler" V3.16.1 package [11] (significant criteria is $p < 0.05$ and $q\text{-value} < 0.05$) and "DOSE" v3.16.0 [12].

Gene set enrichment analysis (GSEA) of the two expression data sets

GSEA is a powerful analytical method to identify whole gene sets, which share common chromosomal location, biological function, or regulation by comparison with knowledge-based databases accumulating large-scale expression data sets [13]. We conducted the GSEA of the two datasets in GO and KEGG respectively. Each analysis performed 1000 times of arrangement of the gene set. The criteria of the significantly enriched gene sets were $P\text{-value} < 0.05$. The GSEA analysis was performed by the "ClusterProiler" V3.16.1 package.

Evaluation of immune cell infiltration

To evaluate the immune cell role and change in the IRI-AKI, we conducted the immune cell infiltration analysis by CIBERSORT method [14]. CIBERSORT can accurately estimate the immune composition of tissue. We conducted this analysis by "CIBERSORT.R" script and visualized the results by "pheatmap" and "ggpubr" R packages.

Construction and analysis of protein and protein interactions (PPI) network

We searched the common DEGs in the online tool STRING (<http://www.string-db.org/>) to construct the PPI network showing interactions between genes or proteins. We conducted the confidence score of 0.4 as the cut-off value, visualized the PPI network of DEGs by Cytoscape software [15]. Cytohubba and CytoNCA [16] plug-in were employed to identify the hub genes separately. We adopted 11 methods (MCC displays a satisfying comparative performance) in Cytohubba and 3 evaluation indexes (degree centrality (DC), betweenness centrality (BC), closeness centrality (CC) applied in the CytoNCA. We further extracted hub modules using another plug-in - Molecular Complex Detection (MCODE) with the cut-off score of 2.

Robust rank aggregation (RRA) method to find the DEGs

We used the de-bias effect, the robust rank aggregation, and probabilistic models to integrate sorted lists of different gene expression profiles from the different protocols or measurement platforms. Based on each gene freely arranged in each data assumption, we scored the rank vector by the order-based statistical analysis and defined the final score of each vector as the minimum p -value. The p -value is corrected to determine whether the ranking of a specific gene is statistically significant,

and multiple checks to assess the stability of the acquired p values. We repeated leave-one-out cross-validation 10,000 times and calculated the averaged p values from all rounds. If a gene ranks high in the results of all DEGs, the smaller p -value was by the RRA method and with the greater probability of the DEGs' robustness. This process was conducted by the "RobustRankAggreg" R package [17].

Transcription factor (TF)-gene interactions and gene-miRNA network of the combined DEGs and hub genes

We constructed the gene-miRNA network and TF-gene interactions of the combined DEGs from RRA analysis and hub genes in the NetworkAnalyst [18] (<https://www.networkanalyst.ca/>), which is a comprehensive web platform for gene expression analysis. The gene-miRNA network is based on the miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/php/download.php>), while TF-gene interactions based on the ENCODE (<http://cistrome.org/BETA/>).

Construction of Drug Gene Interaction network

The Drug Gene Interaction Database (DGIdb) version 3.0.2 (<https://www.dgidb.org>) consolidates, synthesizes, and normalizes drug-gene interactions and gene druggability information from 30 disparate sources [19]. We searched the DEGs genes from the RRA analysis and hub genes in the DGIdb to explore potential drugs or molecular compounds that interacted with the genes. The drug-gene interaction network was visualized by the Cytoscape software.


Results

Identification of differentially expressed genes

After standardization of the two datasets (Figure S1), 239 (187 up-regulated and 52 down-regulated genes) and 384 DEGs (259 up-regulated and 125 down-regulated genes) were extracted from the GSE87024 and GSE34351. PCA score trajectory plots indicated that the IRI and CON groups didn't overlap suggesting the apparent differences between the two groups (Fig. 2 A-B). Heatmaps showed the DEGs could discriminate between the IRI and control (CON) groups (Fig. 2 C-D). The volcano plots visualized the distribution of DEGs (Fig. 2E-F).

Functional and pathway enrichment analysis

For up-regulated genes in GSE87024, the KEGG pathway analysis acquired the 23 significant pathways with the top 3 pathways are TNF signaling pathway, MAPK signaling pathway, and IL-17 signaling pathway (Fig. 3A). Cneplot visualized the conjunction between genes and the enrichment pathway (Fig. 3B). GO functional enrichment analysis showed up-regulated genes were mainly involved in GO terms about the regulation of vasculature development,



response to extracellular stimulus, and intrinsic apoptotic signaling pathway (Fig. 3C). GO Cluster plot showed the interaction between clusters and genes in GO terms (Fig. 3D). Relationships of different GO terms were

visualized in Goplot (Fig. 3E). The down-regulated genes weren't enriched in any pathways.

For GSE34351, up-regulated genes were enriched in 28 significant pathways, including MAPK, IL-17, TNF, and Estrogen signaling pathways (Fig. 4A). Emaplot displayed

the interaction of enriched pathways, and Cneplot visualized the interaction between genes and the enrichment pathways (Fig. 4B-C). Significant enrichment of GO terms included the unfolded protein, regulation of vasculature development, transcription from RNA polymerase II promoter to stress, and topologically incorrect protein (Fig. 4D). GO circle and cluster plot showed the distributions of the genes and GO terms (Fig. 4E-F). No pathway was enriched in the down-regulated genes. Venn diagram showed the common 73 DEGs from the two expressional datasets (Fig. 5A).

Combined DEGs enrichment analysis of GO and KEGG showed the significant pathways involved C-type lectin receptor, NF- κ B, and GnRH signaling pathways (Table S1-2, Fig. 5B-D).

GSEA of the two expression data sets

GSEA of all detected genes in GSE87024 showed that the top KEGG gene set is the PI3K-Akt signaling pathway (Fig. 6A). The other possible mechanisms of IRI-AKI included MAPK signaling pathway and cytokine-cytokine receptor interaction in KEGG (Fig. 6B). The most significantly enriched gene set of GO terms was the mitotic cell cycle regulation (Fig. 6C). The other top 10 enrichment GO terms involved cell growth, upregulation of cell projection organization, T cell activation, and negative regulation of phosphorylation (Fig. 6D). For GSE34351, GSEA analysis of KEGG pathways was similar to the GSE87024 (Fig. 7A-B). GO terms indicated the biological process of the IRI-AKI development related to positive regulation of cellular component biogenesis, reproductive structure development, and positive regulation of MAPK cascade (Fig. 7C-D).

Evaluation of immune cell infiltration

Immune cell infiltration analysis showed plasma cells, T cells CD4 naive decreased in IRI-AKI group, while T cells CD4 memory resting and T cells follicular helper increased in GSE87024. In GSE34351, macrophages M1 elevated while the plasma cells and NK cells reduced in IRI-AKI (Fig. 8).

PPI network and analysis of hub genes and modules

The cluster of the PPI network of common 73 DEGs was composed of 73 nodes and 206 edges (Fig. 9A). The top 10 hub genes selected in the Cytohubba plug-in using the MCC method (score ≥ 5000) and node degree (score ≥ 10) included Activating Transcription Factor 3

(ATF3), FOS, JUN, DNA Damage Inducible Transcript 3 (DDIT3), Activating Transcription Factor 4 (ATF4), Early Growth Response 1 (EGR1), Heme Oxygenase 1 (HMOX1), Heat Shock Protein Family A Member 1B (HSPA1B), JUNB, and Protein Phosphatase 1 Regulatory Subunit 15A (PPP1R15A) (Fig. 9B). Applying CytoNCA, we obtained ten hub genes, namely JUN, ATF3, FOS, EGR1, HMOX1, DDIT3, JUNB, NF- κ B inhibitor zeta (NFKBIZ), PPP1R15A, and C-X-C Motif Chemokine Ligand 1 (CXCL1). Three hub modules were identified and the most significant module had 15 nodes (MCODE score = 6, Fig. 9C-E).

RRA to find the combined DEGs

A total of 25 significant up-regulated genes and two down-regulated genes were identified in the RRA analysis. The heat map showed the expression profile of the top 20 most significant up and down-regulated genes. Each square represented a different gene, and each column represented the expression level of all genes in a data set (Fig. 10).

TF-gene interactions and gene-miRNA network

Gene-miRNA network showed both Adm and Jun modulated by 5 miRNAs, while Egr1 regulated by 3 miRNAs (Fig. 11A). The top 3 targeted DEGs for TFs were Junb, 2410006H16Rik, and Nfkbiz modulated by 26, 18, and 16 TFs separately (Fig. 11B).

Construction of drug gene interaction network

The drug-gene interaction network indicated that JUN, DDIT3, CFRT, FOS, ADM, interact with 44, 26, 22, 10, and 7 drugs or molecular compounds separately. The deferoxamine, glutamine, sirolimus, indomethacin are connected with JUN and DDIT3. (Table S3, Fig. 12).

Discussion

In this study, we screened two expression profiles with the same tissue and similar genetic background mice in early-stage IRI-AKI from the GEO database, adopted RRA analysis to integrate the DEGs for detecting the potential biomarkers and pathways in the pathogenesis of IRI-AKI. We identified the MAPK, TNF, and IL-17 signaling pathways in KEGG database. Regulating the vasculature development, responding to extracellular stimulus, and intrinsic apoptotic signaling pathway were identified

(See figure on next page.)

Fig. 3 Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes analysis (KEGG) enrichment of up-regulated differentially expressed genes (DEGs) in GSE87024. **A** Advanced bubble chart shows significant KEGG pathways of the DEGs. **B** Cneplot visualized the conjunction between genes and the enrichment pathway. **C** Bar chart visualized the GO enrichment significance items of DEGs. **D** GO Cluster plot showed the interaction between clusters and genes in GO terms. **E** GO plot of the interactions between different GO terms




Fig. 3 (See legend on previous page.)




Fig. 4 Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes analysis (KEGG) enrichment of up-regulated differentially expressed genes (DEGs) in GSE34351. **A** Advanced bubble chart shows significant KEGG pathways of the DEGs. **B** Cneplot visualized the conjunction between genes and the enrichment pathways. **C** Emaplot suggested the interaction of enriched pathways. **D** Bar chart visualized the GO enrichment significance items of DEGs. **E** Chord plot shows the distribution of DEGs in different GO terms. Gene symbols are presented on the left side of the graph and fold change values of DEGs are mapped by color scale. Gene involvement in the GO terms was determined by colored connecting lines. **F** GO Cluster plot showed the interaction between clusters and genes in GO terms

in GO database. Further GSEA analysis showed the PI3K-Akt signaling pathway, cytokine-cytokine receptor, positive regulation of cellular component biogenesis, and

reproductive structure development pathway are crucial in IRI-AKI. Combined with the analysis by Cytohubba and CytoNCA, we figured out the JUN, ATF3, FOS,




Fig. 5 Visualization of the enrichment of common differentially expressed genes (DEGs) from two datasets. **A** Venn diagram presents a combination of all differentially expressed genes of two datasets. **B** Bar chart shows the significant KEGG pathways enriched by the 73 DEGs. **C** Bubble chart displays the significant GO terms. **D** GO plot shows the interacts with different enriched GO terms




Fig. 6 Visualization of the gene set enrichment analysis (GSEA) of the GSE87024. **A** GSEA plots shows the most enriched gene sets in KEGG of all detected genes in the GSE87024. **B** The top 10 most significant up-regulated enriched gene sets in KEGG. **C** The top terms enriched in GO database. **D** The top 10 most significantly enriched terms in GO database





Fig. 7 Visualization of the gene set enrichment analysis (GSEA) of the GSE34351. **A** GSEA plots shows the most enriched gene sets in KEGG of all detected genes in the GSE34351. **B** The top 10 most significant up-regulated enriched gene sets in KEGG. **C** The top terms enriched in GO database. **D** The top 10 most significantly enriched terms in GO database

EGR1, HMOX1, DDIT3, JUNB, NFKBIZ, PPP1R15A, CXCL1, ATF4, and HSPA1B as hub genes.

GO, KEGG and GSEA analysis showed that the MAPK, TNF and IL-17 signaling pathways are crucial in IRI-AKI development. MAPK signaling pathway consists of four


branches, namely ERK, JNK, p38, and ERK5. Activation of p38 and JNK signaling is a feature of acute kidney disease. The relative levels of JNK, p38, and ERK activation have been considered to determine cell fate after kidney damage. Selective inhibitors of p38 MAPK seemed



to be effective in rodent models of acute kidney disease [20]. Remote ischemic pretreatment plays a role in preventing IRI from developing through activating JNK, p38, and MAPK kinase [21]. Several drugs or molecular compounds mitigate IRI via the MAPK pathway [22, 23]. TNF, considered as a crucial mediator in cell proliferation, cell death, and differentiation, interacts with two cell surface receptors: TNFR1 and TNFR2 (TNFRs) [24]. Studies showed the level of circulating TNF was increased during IRI-AKI causing renal cell damage via neutrophil-mediated inflammatory injury and apoptosis [25]. IRI mice with genetic deletion of TNFR1 displayed a significant lessening in renal injury and inflammation


[26]. Pretreatment soluble TNFR2 fusion protein to neutralize TNF- α mitigate renal injury in IRI rats [27]. The IL-17 family consists of six members IL-17A-F and five members IL-17R A-E form the IL-17 receptor family. Researches showed IL-17A activation in IRI mice may promote inflammation activity. Administration of a neutralizing monoclonal anti-IL-17A antibody can attenuate renal damage by reducing pro-inflammatory mediators and enhancing renal and circulation levels of anti-inflammatory cytokines [28, 29]. Further researches are needed to detect the function of these pathways in IRI-AKI.

We identified 10 hub genes in IRI-AKI with one biomarker (Atf3) has been studied in IRI-AKI, five



biomarkers (Cxcl1 and Jun, Fos, Nfkbiz, Hmox1) were researched in other types of AKI, 2 genes (Atf4 and Egr1) play role in I/R injury of other organs and three genes (Ppp1r15a, Hspa1b, and Ddit3) had not been reported in AKI or IRI researches. Atf3 could protect against IRI-AKI via suppressing p53 and inducing p21. In vitro studies showed it attenuated cell apoptosis by interacting with Nicotiflorin [30, 31]. CXCL1-CXCR2 signaling axis played an important role in alleviating cisplatin-induced

AKI by regulation of inflammatory response [32]. Jun was studied in acute kidney injury including aristolochic acid-induced AKI, crush syndrome induced AKI, and myoglobinuric AKI but not IRI-AKI [33–35]. Inhibitor of c-Fos/activator protein-1 could decrease the production of TNF- α and other downstream molecules, which protect against LPS-AKI [36]. FosB induced the elevated expression of matrix metalloproteinase-2 in the cardiac IRI mice [37]. Studies found the NF- κ B/miR-376b/NFKBIZ




negative feedback loop adjusted intrarenal inflammation and alleviated renal damage in septic AKI [38]. HMOX1 long GT tandem repeats are associated with the occurrence of AKI in sickle cell anemia people [39]. Atf4 was related to endoplasmic reticulum stress, amino acid starvation, mitochondrial stress, and oxidative stress. It was reported that MIF-2/D-DT increased proximal tubular cell regeneration via ATF4-dependent pathways in IRI mice [40]. Egr1 was mainly studied in myocardial IRI and it may serve as a major regulator of remote preconditioning [41]. For Ppp1r15a, Hspa1b, and Ddit3, we haven't found any related AKI or IRI studies, which should be further verified in experimental studies.

In the gene-miRNA network analysis, mmu-mir-138-5p was found continuously increased in urine samples of rats daily administrated with gentamicin [42]. Researches showed that miR-709 was significantly upregulated in the proximal tubular cells of human and mice when suffering AKI [43]. However, there was no article about the roles of those miRNAs on IRI-AKI. Further studies were needed to examine the effects of these miRNAs on IRI-AKI.

We first conducted the drug-gene interaction network to identify the potential targets of IRI - AKI. Our results showed that staurosporine is a common molecular compounds interacting with CXCL2 and DDIT3. Considered as a protein kinase C inhibitor, staurosporine could protect against the impairment of working memory in IRI gerbils and rats [44, 45]. Curcumin interacts with both DDIT3 and cystic fibrosis transmembrane conductance regulator (CFTR). It is a diketone compound extracted from the plant turmeric. Some animal studies have shown that curcumin can protect the I/R injury and toxin-induced injury [46, 47]. Nowadays, researchers have designed a stepwise-targeting chitosan oligosaccharide conjugate, which can convey curcumin to renal tubular epithelial cells and remove excessive reactive oxygen species (ROS), to treat acute kidney injury [48]. Crofelemer, an inhibitor of the CFTR, was applied to alleviate pain in women with irritable bowel syndrome-diarrhea (IBS-D) as well as treat noninfectious diarrhea in HIV-positive patients receiving antiretroviral therapy [49]. Further studies should be conducted to discover the

A



B





Fig. 11 The networks of target gene-miRNA and TF-gene interactions. **A** Target gene-miRNA network. The pink circle nodes are the genes, and the blue octagon nodes are the miRNAs. **B** TF-gene interactions network. The red circle nodes are the genes, and blue octagon nodes are the transcription factors (TFs)



roles of the drugs or molecular compounds as potential therapeutic targets.

Our study have some strengths. First, we screened all the datasets about the IRI-AKI in GEO and focused on the early onset of this disease selecting the mice with similar genetic background to reduce individual differences. Second, we applied multiple bioinformatic methods to identify common DEGs that are potentially involved in the disease. In our limited knowledge, this was the first study applied the RRA analysis, a robust and compelling approach to integrate different datasets on IRI - AKI. Third, we performed the GSEA method utilizing all genetic expression information in datasets to find the crucial pathways in IRI-AKI. Different methods are applied to detect the hub genes and hub modules. Forth, we further analyzed the target genes for miRNA/TF. Fifth, we analyzed the signature of the immune cell in and found the T cell increasing in IRI-AKI. Last, we first conducted the drug-gene interaction

network and identified 116 drugs or compounds as potential therapeutic targets of IRI-AKI giving new insights for further study.

There were some limitations in our study. First, to aggragate samples with similar genetic background mice and IRI-AKI occurrence time, we only selected two datasets and extracted a total of 12 samples. Though different times of IRI in GSE87024, we chose the earliest time after IRI-AKI to analyze. Since the limited sample numbers, we can't apply the weighted gene co-expression network analysis (WGCNA) to construct gene co-expression networks in our study. Second, we focused on the microarray and didn't include the RNA-seq, so we lack the data of miRNA and lncRNA. However, we constructed the TF-gene interactions and gene-miRNA network utilizing the open database. Third, the DEGs acquired from the RRA analysis are limited, we didn't perform further GO and KEGG pathway analysis. Fourth, we didn't validate

the hub genes identified in this study in AKI patients or experiment, which is a part of our future work.

Conclusions

To conclude, our study identified 10 hub genes and 3 modules, key pathways involved in early IRI-AKI diagnosis and treatment utilizing various bioinformatic methods. We constructed the immune landscape and provided new insights and implications for further experimental confirmation.

Abbreviations

AKI: Acute kidney injury; ATF3: Activating Transcription Factor 3; ATF4: Activating Transcription Factor 4; CON: Control; CXCL1: C Motif Chemokine Ligand 1; DDIT3: DNA Damage Inducible Transcript 3; DEGs: Differentially expressed genes; DGIdb: Drug Gene Interaction Database; EGR1: Early Growth Response 1; GO: Gene ontology; GSEA: Gene set enrichment analysis; HMOX1: Heme Oxygenase 1; HSPA1B: Heat Shock Protein Family A Member 1B; IBS-D: Irritable bowel syndrome-diarrhea; IL-17: Interleukin-17; IL-18: Interleukin-18; IRI: Ischemia/reperfusion injury; KEGG: Kyoto Encyclopedia of Genes and Genomes; KIM-1: Kidney injury molecule-1; MAPK: Mitogen-activated protein kinase; MCODE: Molecular Complex Detection; NGAL: Neutrophil gelatinase-associated lipocalin; NFKBIZ: NF-kappa-B inhibitor zeta; PCA: Principal components analysis; PPI: Protein and protein interactions; PPP1R15A: Protein Phosphatase 1 Regulatory Subunit 15A; ROS: Reactive oxygen species; RRA: Robust rank aggregation; TF: Transcription factor; TNF: Tumor necrosis factor; WGCNA: Weighted gene co-expression network analysis.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s41065-022-00236-x>.

Additional file 1: Table S1 KEGG enrichment outcomes of the common genes. **Table S2** GO analysis of the common genes. **Table S3** Drug gene interactions of the DEGs acquired from the RRA analysis and hub genes.

Additional file 2: Figure S1 Box plots of the gene expression data after normalization.

Acknowledgements

Not applicable

Author's contributions

RL You conceived and designed the study, performed the study, analyzed the data, wrote the paper, prepared figures and/or tables. ZG HeYang, YX Ma performed the study; Hua Zheng, JF Lin, PL Ji analyzed data; LM Chen conceived and designed the study, wrote the paper, reviewed drafts of the paper. The author(s) read and approved the final manuscript.

Funding

This work was partially supported by grants from the National Natural Scientific Foundation of China (82170709, 81970607 to C.L.); CAMS Innovation Fund for Medical Sciences (CIFMS 2020-I2M-C&T-A-001, 2021-I2M-1-003 to C.L.); Capital's Funds for Health Improvement and Research (CFH 2020-2-4018 to C.L.); Beijing Natural Science Foundation (L202035 to C.L.); The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its Supplementary information files.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China. ²Department of Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.

Received: 4 December 2021 Accepted: 29 April 2022

Published online: 04 June 2022

References

- Al-Jaghbeer M, Dealmeida D, Bilderback A, Ambrosino R, Kellum JA. Clinical decision support for in-hospital AKI. *J Am Soc Nephrol*. 2018;29(2):654–60.
- Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med*. 2015;41(8):1411–23.
- Zheng L, Gao W, Hu C, Yang C, Rong R. Immune cells in ischemic acute kidney injury. *Curr Protein Pept Sci*. 2019;20(8):770–6.
- Pefanis A, Ierino FL, Murphy JM, Cowan PJ. Regulated necrosis in kidney ischemia-reperfusion injury. *Kidney Int*. 2019;96(2):291–301.
- Gonzalez SR, Cortes AL, Silva RCD, Lowe J, Prieto MC, Silva Lara LD. Acute kidney injury overview: From basic findings to new prevention and therapy strategies. *Pharmacol Ther*. 2019;200:1–12.
- Jia P, Wu X, Pan T, Xu S, Hu J, Ding X. Uncoupling protein 1 inhibits mitochondrial reactive oxygen species generation and alleviates acute kidney injury. *EBioMedicine*. 2019;49:331–40.
- Orlando G, Danger R, Okut H, Edgar L, Bussolati B, Gall E, Bergman CR, Tamburrini R, Gazia C, Farney AC, et al. Molecular pathways underlying adaptive repair of the injured kidney: novel donation after cardiac death and acute kidney injury platforms. *Ann Surg*. 2020;271(2):383–90.
- Wang J, Gao P, Song Y, Sun J, Chen X, Yu H, Wang Y, Wang Z. Prognostic value of gastric cancer-associated gene signatures: evidence based on a meta-analysis using integrated bioinformatics methods. *J Cell Mol Med*. 2018;22(11):5743–7.
- Liu Y, Chen TY, Yang ZY, Fang W, Wu Q, Zhang C. Identification of hub genes in papillary thyroid carcinoma: robust rank aggregation and weighted gene co-expression network analysis. *J Transl Med*. 2020;18(1):170.
- Gholamnejad A, Abdul Tehrani H, Gholami Fesharaki M. Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies. *J Nephrol*. 2018;31(6):813–31.
- Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS*. 2012;16(5):284–7.
- Yu G, Wang LG, Yan GR, He QY. DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. *Bioinformatics*. 2015;31(4):608–9.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005;102(43):15545–50.
- Gong K, Xia M, Wang Y, Bai L, Ying W, Zhu F, Chen Y. Importance of glycosylation in the interaction of Tamm-Horsfall protein with collectin-11 and acute kidney injury. *J Cell Mol Med*. 2020;24(6):3572–81.

15. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 2003;13(11):2498–504.
16. Tang Y, Li M, Wang J, Pan Y, Wu FX. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. *BioSyst.* 2015;127:67–72.
17. Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. *Bioinformatics.* 2012;28(4):573–80.
18. Xia J, Gill EE, Hancock RE. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. *Nat Protoc.* 2015;10(6):823–44.
19. Cotto KC, Wagner AH, Feng YY, Kiwala S, Coffman AC, Spies G, Wolfram A, Spies NC, Griffith OL, Griffith M. DGldb 3.0: a redesign and expansion of the drug-gene interaction database. *Nucleic Acids Res.* 2018;46(D1):D1068–d1073.
20. Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, Nikolic-Paterson DJ. Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. *J Am Soc Nephrol.* 2003;14(2):338–51.
21. Park KM, Chen A, Bonventre JV. Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. *J Biol Chem.* 2001;276(15):11870–6.
22. Wang C, Hao Z, Zhou J, Zhang L, Sun Y, Liang C. Rutaecarpine alleviates renal ischemia reperfusion injury in rats by suppressing the JNK/p38 MAPK signaling pathway and interfering with the oxidative stress response. *Mol Med Rep.* 2017;16(1):922–8.
23. Chen J, Wang W, Zhang Q, Li F, Lei T, Luo D, Zhou H, Yang B. Low molecular weight fucoidan against renal ischemia-reperfusion injury via inhibition of the MAPK signaling pathway. *PLoS One.* 2013;8(2):e56224.
24. Al-Lamki RS, Mayadas TN. TNF receptors: signaling pathways and contribution to renal dysfunction. *Kidney Int.* 2015;87(2):281–96.
25. Inoue T, Abe C, Sung S-SJ, Moscalu S, Jankowski J, Huang L, Ye H, Rosin DL, Guyenet PG, Okusa MD. Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through α 7nAChR+ splenocytes. *J Clin Invest.* 2016;126(5):1939–52.
26. Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, Esposito E. The renal injury and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF- α R1: a comparison with infliximab treatment. *Eur J Pharmacol.* 2013;700(1–3):134–46.
27. Choi DE, Jeong JY, Lim BJ, Na KR, Shin YT, Lee KW. Pretreatment with the tumor necrosis factor- α blocker etanercept attenuated ischemia-reperfusion renal injury. *Transplant Proc.* 2009;41(9):3590–6.
28. Xue L, Xie K, Han X, Yang Z, Qiu J, Zhao Z, Bao T. Detrimental functions of IL-17A in renal ischemia-reperfusion injury in mice. *J Surg Res.* 2011;171(1):266–74.
29. Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, Strieter RM, Rosin DL, Okusa MD. IL-17 produced by neutrophils regulates IFN- γ -mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. *J Clin Invest.* 2010;120(1):331–42.
30. Yoshida T, Sugiura H, Mitobe M, Tsuchiya K, Shirota S, Nishimura S, Shiohira S, Ito H, Nobori K, Gullans SR, et al. ATF3 protects against renal ischemia-reperfusion injury. *J Am Soc Nephrol.* 2008;19(2):217–24.
31. Wang L, Li C, Guan C, Zhang Y, Yang C, Zhao L, Luan H, Zhou B, Che L, Wang Y, et al. Nicotiflorin attenuates cell apoptosis in renal ischemia-reperfusion injury through ATF3. *Nephrology (Carlton).* 2021;226(4):358–68.
32. Liu P, Li X, Lv W, Xu Z. Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response. *Biomed Pharmacother.* 2020;122:109693.
33. Zhai W, Xu YF, Peng B, Zhang HM, Huang JH, Liu M, Wang GC, Zheng JH. Effect of free radical scavenger on c-jun activation in rats with crush syndrome. *Int J Clin Pharmacol Ther.* 2013;51(7):600–5.
34. Yang F, Ozols E, Ma FY, Leong KG, Tesch GH, Jiang X, Nikolic-Paterson DJ. c-Jun Amino Terminal Kinase Signaling Promotes Aristolochic Acid-Induced Acute Kidney Injury. *Front Physiol.* 2021;12:599114.
35. Kim YS, Jung MH, Choi MY, Kim YH, Sheverdin V, Kim JH, Ha HJ, Park DJ, Kang SS, Cho GJ, et al. Glutamine attenuates tubular cell apoptosis in acute kidney injury via inhibition of the c-Jun N-terminal kinase phosphorylation of 14-3-3. *Crit Care Med.* 2009;37(6):2033–44.
36. Miyazaki H, Morishita J, Ueki M, Nishina K, Shiozawa S, Maekawa N. The effects of a selective inhibitor of c-Fos/activator protein-1 on endotoxin-induced acute kidney injury in mice. *BMC Nephrol.* 2012;13:153.
37. Alfonso-Jaume MA, Bergman MR, Mahimkar R, Cheng S, Jin ZQ, Karliner JS, Lovett DH. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. *Am J Physiol Heart Circ Physiol.* 2006;291(4):H1838–1846.
38. Liu Z, Tang C, He L, Yang D, Cai J, Zhu J, Shu S, Liu Y, Yin L, Chen G, et al. The negative feedback loop of NF- κ B/miR-376b/NFKBIZ in septic acute kidney injury. *JCI Insightv.* 2020;5(24):e142272.
39. Saraf SL, Viner M, Rischall A, Raslan R, Shah BN, Zhang X, Han J, Gowhari M, Jain S, Molokie RE, et al. HMOX1 and acute kidney injury in sickle cell anemia. *Blood.* 2018;132(15):1621–5.
40. Ochi A, Chen D, Schulte W, Leng L, Moeckel N, Pnecychna M, Averdunk L, Stoppe C, Bucala R, Moeckel G. MIF-2/D-DT enhances proximal tubular cell regeneration through SLPI- and ATF4-dependent mechanisms. *Am J Physiol Renal Physiol.* 2017;313(3):F767–f780.
41. Billah M, Ridiandries A, Rayner BS, Allahwala UK, Dona A, Khachigian LM, Bhandi R. Egr-1 functions as a master switch regulator of remote ischemic preconditioning-induced cardioprotection. *Basic Res Cardiol.* 2019;115(1):3.
42. Zhou X, Qu Z, Zhu C, Lin Z, Huo Y, Wang X, Wang J, Li B. Identification of urinary microRNA biomarkers for detection of gentamicin-induced acute kidney injury in rats. *Regul Toxicol Pharmacol.* 2016;78:78–84.
43. Guo Y, Ni J, Chen S, Bai M, Lin J, Ding G, Zhang Y, Sun P, Jia Z, Huang S, et al. MicroRNA-709 mediates acute tubular injury through effects on mitochondrial function. *J Am Soc Nephrol.* 2018;29(2):449–61.
44. Ohno M, Yamamoto T, Watanabe S. Effect of staurosporine, a protein kinase C inhibitor, on impairment of working memory in rats exposed to cerebral ischemia. *Eur J Pharmacol.* 1991;204(1):113–6.
45. Hara H, Onodera H, Yoshidomi M, Matsuda Y, Kogure K. Staurosporine, a novel protein kinase C inhibitor, prevents postischemic neuronal damage in the gerbil and rat. *J Cereb Blood Flow Metab.* 1990;10(5):646–53.
46. Awad AS, El-Sharif AA. Curcumin immune-mediated and anti-apoptotic mechanisms protect against renal ischemia/reperfusion and distant organ induced injuries. *Int Immunopharmacol.* 2011;11(8):992–6.
47. Kumar P, Sulakhiya K, Barua CC, Mundhe N. TNF- α , IL-6 and IL-10 expressions, responsible for disparity in action of curcumin against cisplatin-induced nephrotoxicity in rats. *Mol Cell Biochem.* 2017;431(1–2):113–22.
48. Wang DW, Li SJ, Tan XY, Wang JH, Hu Y, Tan Z, Liang J, Hu JB, Li YG, Zhao YF. Engineering of stepwise-targeting chitosan oligosaccharide conjugate for the treatment of acute kidney injury. *Carbohydr Polym.* 2021;256:117556.
49. Nee J, Salley K, Ludwig AG, Sommers T, Ballou S, Takazawa E, Duehren S, Singh P, Iturrino J, Katon J, et al. Randomized clinical trial: crolefemer treatment in women with diarrhea-predominant irritable bowel syndrome. *Clin Transl Gastroenterol.* 2019;10(12):e00110.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

